RTOG-1205

Trial

Clinical Trial Title

RTOG-1205

Trial Status

Open to Enrollment

Start Date

April 2, 2013

Location

Trial Type

Cancer (Oncology)

Specific Condition

Recurrent Glioblastoma

Description

A Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Eligibility Criteria

  • Does patient have progression on contrast-enhanced MRI/CT within 14 days prior to registration as defined in section  
  • Is there an interval of 6 months or greater between completion of prior radiotherapy and registration

  • Has patient recovered from the toxic effects of prior therapy?

  •  Is the patient’s age ≥18?

 

 

IRB Number

Legacy IRB

Notes

Sponsored by: Radiation Therapy Oncology Group

Principal Investigator Name

Andrew Kee, MD

Contact Name

Legacy Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Last Updated: Wednesday, September 18, 2013 01:41:02 PM

We'd like to make your experience better.
x

Help us improve our site and be entered to win a $100 gift card.

Take the Survey